losartan has been researched along with Right Ventricular Dysfunction in 9 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| " The current study aimed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysfunction in adults after repaired tetralogy of Fallot." | 9.27 | Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy ( Berbee, JK; Boekholdt, SM; Bokma, JP; Bouma, BJ; Groenink, M; Meijboom, FJ; Mulder, BJM; Post, MC; van Dijk, AP; van Melle, JP; Vliegen, HW; Winter, MM; Zwinderman, AH, 2018) |
| " The current study aimed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysfunction in adults after repaired tetralogy of Fallot." | 5.27 | Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy ( Berbee, JK; Boekholdt, SM; Bokma, JP; Bouma, BJ; Groenink, M; Meijboom, FJ; Mulder, BJM; Post, MC; van Dijk, AP; van Melle, JP; Vliegen, HW; Winter, MM; Zwinderman, AH, 2018) |
| "The REDEFINE is an investigator-initiated, multicenter, prospective, randomized, double-blind, placebo-controlled trial to study the effects of the angiotensin II receptor blocker losartan (target dosage of 150 mg once daily) in adult patients with TOF." | 2.84 | Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system (REDEFINE) trial: Rationale and design of a randomized, double-blind, placebo-controlled clinical trial. ( Berbee, JK; Bokma, JP; Bouma, BJ; Kornaat, EM; Meijboom, FJ; Mulder, BJM; Post, MC; van Dijk, AP; van Melle, JP; Vliegen, HW; Winter, MM; Zwinderman, AH, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Akazawa, Y | 1 |
| Fujioka, T | 1 |
| Ide, H | 1 |
| Yazaki, K | 1 |
| Honjo, O | 2 |
| Sun, M | 2 |
| Friedberg, MK | 2 |
| Bokma, JP | 2 |
| Winter, MM | 2 |
| Kornaat, EM | 1 |
| Vliegen, HW | 2 |
| van Dijk, AP | 2 |
| van Melle, JP | 2 |
| Meijboom, FJ | 2 |
| Post, MC | 2 |
| Berbee, JK | 2 |
| Zwinderman, AH | 2 |
| Mulder, BJM | 2 |
| Bouma, BJ | 2 |
| Boekholdt, SM | 1 |
| Groenink, M | 1 |
| Reddy, S | 1 |
| Bernstein, D | 1 |
| Newburger, JW | 1 |
| Cho, MY | 1 |
| Li, J | 1 |
| Assad, RS | 1 |
| Rohailla, S | 1 |
| Apitz, C | 1 |
| Redington, AN | 1 |
| Borgdorff, MA | 1 |
| Bartelds, B | 1 |
| Dickinson, MG | 1 |
| Steendijk, P | 1 |
| Berger, RM | 1 |
| Butorov, IV | 1 |
| Verbitskiĭ, ON | 1 |
| Butorov, SI | 1 |
| Paraska, VI | 1 |
| Dore, A | 1 |
| Houde, C | 1 |
| Chan, KL | 1 |
| Ducharme, A | 1 |
| Khairy, P | 1 |
| Juneau, M | 1 |
| Marcotte, F | 1 |
| Mercier, LA | 1 |
| Rouleau, JL | 1 |
| Kapuku, G | 1 |
| Pelletier, S | 1 |
| Gosselin, H | 1 |
| Adam, A | 1 |
| Gagnon, C | 1 |
| Lambert, C | 1 |
| Meloche, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System[NCT02010905] | Phase 2 | 120 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| Prospective Comparison of ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure[NCT05117736] | 48 participants (Anticipated) | Interventional | 2022-03-15 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for losartan and Right Ventricular Dysfunction
6 other studies available for losartan and Right Ventricular Dysfunction
| Article | Year |
|---|---|
Impaired right and left ventricular function and relaxation induced by pulmonary regurgitation are not reversed by tardive antifibrosis treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Echocardiography; Fibrosis | 2021 |
Renin-Angiotensin-Aldosterone System Inhibitors for Right Ventricular Dysfunction in Tetralogy of Fallot: Quo Vadis?
Topics: Adult; Double-Blind Method; Humans; Losartan; Renin-Angiotensin System; Tetralogy of Fallot; Ventric | 2018 |
Adverse biventricular remodeling in isolated right ventricular hypertension is mediated by increased transforming growth factor-β1 signaling and is abrogated by angiotensin receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Connective Tissue Growth Factor; Endoth | 2013 |
A cornerstone of heart failure treatment is not effective in experimental right ventricular failure.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Failure; Losartan; Mal | 2013 |
[Efficacy of losartan treatment of right ventricular cardiac insufficiency in patients with chronic obstructive bronchitis].
Topics: Adult; Angiotensin II; Bronchitis, Chronic; Drug Therapy, Combination; Hemodynamics; Humans; Losarta | 2003 |
Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2001 |